Skip to main content
. 2014 Aug 6;124(14):2271–2279. doi: 10.1182/blood-2014-05-575878

Figure 1.

Figure 1

12-LOX modulates FcγRIIa-mediated platelet aggregation. (A) The aggregation of washed human platelets was measured following FcγRIIa crosslinking (IV.3 + GAM) in the presence of increasing concentrations of ML355, a 12-LOX inhibitor, ranging from 1 to 20 μM (n = 5) or DMSO (vehicle control, n = 5). The left panel shows the representative dose response of ML355 affecting FcγRIIa-induced aggregation. The right panel is a composite of ML355 doses. (B) Following FcγRIIa crosslinking (IV.3 + GAM), the production of 12-HETE, the predominant 12-LOX oxylipin, was measured in platelets pretreated with concentrations of ML355 ranging from 1 to 20 μM (n = 4) or DMSO (n = 4). (C) 12-HETE production was measured in FcγRIIa crosslinked platelets at increasing time points in the presence of DMSO or ML355 (20 μM) (n = 4). (D) Washed human platelets were pretreated with DMSO (n = 4) or ML355 (20 μM) (n = 8) and platelet aggregation was measured following FcγRIIa stimulation (anti-CD9). Error bars indicate SEM. *P < .05; **P < .01.